Literature DB >> 17984931

Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians.

Mohamad K Nusier1, Abdelrahman M Radaideh, Nida'a A Ababneh, Bara'ah M Qaqish, Renad Alzoubi, Yousef Khader, Janet Y Mersa, Nidal M Irshaid, Mohammed El-Khateeb.   

Abstract

Factor V Leiden and prothrombin G20210A are related genetic risk factors for venous thromboembolism (VTE). Analysis for both mutations is increasingly being performed on patients exhibiting hypercoagulability. The objective of this study was to determine the prevalence of factor V Leiden (FVL), prothrombin-G20210A (PT-G20210A) polymorphisms and their coexistence among apparently healthy Jordanians. One thousand apparently healthy individuals from representative regions of Jordan with no previous history of VTE participated in this study. The mean age of participants was 28.5+/-6.4 years (age range 18-45 years). Two hundred and eighteen subjects were APC resistant with an APC-R mean of 85.52+/-15.35 seconds; the non-resistant subjects had an APC-R mean of 159.90+/-26.96 seconds. A multiplex polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for the simultaneous detection of FVL and prothrombin G20210A was used to analyze the 218 DNA samples that were APC-R resistant. Both mutations generate HindIII RFLPs and the prothrombin amplicon contains an invariant HindIII recognition sites. The multiplex PCR-RFLP of Factor V for those 218-samples was: 41 wild-type, 169 heterozygous mutant, and eight homozygous mutant individuals. For prothrombin G20210A, the multiplex PCR-RFLP identified 215 wild-type and three heterozygous mutant individuals. Factor V positive individuals (n=50) had a mean F-V activity of 78.04%+/-25.81. F-V activity among wild type (n=41), F-V Leiden heterozygous (n=169) and F-V Leiden homozygous (n=8) were 92.93%+/-16.17, 87.02%+/-15.21 and 96.14%+/-12.32, respectively. Factor II positive subjects (n=47) had a mean factor II activity of 127.96%+/-21.37. F-II activity among carriers (heterozygous, n=3) and non-carriers (normal, n=215) of PT-G20210A mutation were 107.67%+/-9.29 and 105.00%+/-17.79, respectively. The prevalence of FVL was 21.8% and there is a little likelihood of the co-inheritance of the FVL and PT-G20210A among healthy young adults, since only few cases were found to be carriers for the two alleles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984931

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  5 in total

1.  High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T.

Authors:  Ayman S Hussein
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Prevalence of factor V Leiden in south Tunisian blood donors.

Authors:  Lobna Maalej; Basma Hadjkacem; Ikram Ben Amor; Mariem Smaoui; Ali Gargouri; Jalel Gargouri
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

3.  Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan.

Authors:  Rana Dajani; Raja Fatahallah; Abdelrahman Dajani; Mohammad Al-Shboul; Yousef Khader
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

4.  Prevalence of positive factor V Leiden and prothrombin mutations in samples tested for thrombophilia in Saudi Arabia.

Authors:  Fatimah Madkhaly; Abdulaziz Alshaikh; Hala Aba Alkhail; Randa Alnounou; Tarek Owaidah
Journal:  Am J Blood Res       Date:  2021-06-15

5.  Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.